Patent: 7,498,414
✉ Email this page to a colleague
Summary for Patent: 7,498,414
| Title: | Human antibodies specific to KDR and uses thereof |
| Abstract: | The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal. |
| Inventor(s): | Zhenping Zhu |
| Assignee: | ImClone LLC |
| Application Number: | US10/506,997 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,498,414
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Company | CYRAMZA | ramucirumab | Injection | 125477 | 21-Apr-14 | 7,498,414 | 2023-03-04 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
